Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Holdings Raised by State Street Corp

State Street Corp increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 61.4% during the third quarter, HoldingsChannel reports. The firm owned 1,680,229 shares of the company’s stock after acquiring an additional 638,955 shares during the period. State Street Corp’s holdings in Fulcrum Therapeutics were worth $5,998,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. purchased a new position in shares of Fulcrum Therapeutics during the third quarter valued at $721,000. Centiva Capital LP acquired a new stake in Fulcrum Therapeutics during the 3rd quarter worth about $273,000. Braidwell LP purchased a new position in Fulcrum Therapeutics during the 3rd quarter valued at about $3,817,000. Verition Fund Management LLC acquired a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at about $134,000. Finally, Walleye Capital LLC purchased a new stake in shares of Fulcrum Therapeutics in the third quarter worth approximately $59,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on FULC. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald lowered Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Leerink Partnrs cut Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Bank of America lowered Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $10.00 to $2.00 in a research report on Thursday, September 12th. Finally, Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the company from $22.00 to $3.00 in a report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Fulcrum Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Trading Down 1.0 %

Shares of NASDAQ:FULC opened at $4.79 on Friday. The firm has a market capitalization of $258.37 million, a PE ratio of -15.45 and a beta of 2.14. Fulcrum Therapeutics, Inc. has a 1-year low of $2.86 and a 1-year high of $13.70. The business’s 50 day moving average is $3.70 and its 200-day moving average is $5.68.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.